News blog

Committee votes to withdraw approval for breast cancer drug

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted today to move forward with its December decision to withdraw approval for the drug Avastin in the treatment of metastatic breast cancer. The committee’s vote was unanimous on the grounds that the available evidence doesn’t show that the drug is effective enough to justify serious toxic side effects, including severe high blood pressure, hemorrhage and heart failure. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE